SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

SU

239.5

+4.54%↑

BAS

50.94

-2.75%↓

REP

23.49

-4.74%↓

AM

337.8

+5.96%↑

EXE.US

106.63

-4.13%↓

Search

Eurofins Scientific SE

Abrir

64.9 3.84

Visão Geral

Variação de preço das ações

24h

Atual

Mín

62.48

Máximo

65.34

Indicadores-chave

By Trading Economics

Rendimento

105M

228M

Vendas

1.9B

3.7B

P/E

Médio do Setor

23.828

69.273

Rendimento de Dividendos

1.18

Margem de lucro

6.2

Funcionários

65,694

EBITDA

285M

693M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+17.08% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.18%

3.43%

Próximos Ganhos

1 de abr. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.8B

11B

Abertura anterior

61.06

Fecho anterior

64.9

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

Eurofins Scientific SE Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mar. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Nike, RH, NCino

31 de mar. de 2026, 22:35 UTC

Ganhos

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 de abr. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 de mar. de 2026, 23:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 de mar. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 de mar. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 de mar. de 2026, 23:21 UTC

Ganhos

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 de mar. de 2026, 23:14 UTC

Conversa de Mercado
Ganhos

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 de mar. de 2026, 23:12 UTC

Conversa de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss Widens >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 de mar. de 2026, 21:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 de mar. de 2026, 21:36 UTC

Conversa de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 de mar. de 2026, 21:33 UTC

Ganhos

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 de mar. de 2026, 21:32 UTC

Ganhos

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 de mar. de 2026, 21:28 UTC

Ganhos

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 de mar. de 2026, 21:26 UTC

Ganhos

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 de mar. de 2026, 21:25 UTC

Ganhos

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 de mar. de 2026, 21:24 UTC

Conversa de Mercado
Ganhos

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 de mar. de 2026, 21:21 UTC

Ganhos

Nike's Digital Channel Still Too Promotional, CFO Says

31 de mar. de 2026, 21:20 UTC

Ganhos

Nike CEO: Converse Remains Important to Portfolio

Comparação entre Pares

Variação de preço

Eurofins Scientific SE Previsão

Preço-alvo

By TipRanks

17.08% parte superior

Previsão para 12 meses

Média 73.43 EUR  17.08%

Máximo 81 EUR

Mínimo 64 EUR

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Eurofins Scientific SE - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

2

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

54.22 / 56.82Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Eurofins Scientific SE

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
help-icon Live chat